Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

Launched by MINIA UNIVERSITY · May 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different treatment approaches are for patients with resectable pancreatic cancer, which means that the tumor can be surgically removed. The trial compares immediate surgery to a treatment called neoadjuvant chemotherapy, where patients receive chemotherapy before surgery. Researchers want to find out if starting with chemotherapy helps patients live longer compared to having surgery first, followed by more chemotherapy after.

To be eligible for the trial, participants must be between 65 and 74 years old, and they must have a confirmed diagnosis of pancreatic cancer that is resectable, meaning the tumor isn’t touching important blood vessels. Unfortunately, individuals with certain types of more advanced pancreatic cancer or those who aren’t healthy enough for surgery cannot participate. If someone joins the study, they can expect to undergo either immediate surgery or chemotherapy before surgery, with ongoing support and monitoring throughout the process. This trial is currently looking for participants to help answer important questions about the best way to treat this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Computed tomography (CT) with pancreatic protocol + vascular mapping
• • Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.
• Exclusion Criteria:
• • Borderline resectable \& locally advanced pancreatic cancer
• • Tumor at the tail of the pancreas.
• • Metastatic pancreatic cancer
• • Unfit patients for surgery.